Establishment Labs Holdings Inc.
HealthcareNASDAQ:ESTA · NASDAQ Capital Market
-$2.97 today
Vol 0.47M · Avg 0.50M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-216.9%
avg 63.7%
ROIC
-11.9%
avg -37.6%
ROA
-14.3%
avg -34.4%
Analysis
ROIC is currently the strongest return metric at -11.9% versus its period average of -37.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Juan Jose Chacon Quiros | Founder & Executive Director | $2.00M | — | 54 | $927,504.00 | 3.15% |
Fillipo Peter Caldini | Chief Executive Officer & Director | $1.18M | — | 61 | $43,430.00 | 0.15% |
Rajbir Singh Denhoy | Senior Vice President of Global Strategy | $645,514.00 | — | 56 | $23,348.00 | 0.08% |
S. Ross Mansbach | General Counsel, Chief Compliance Officer & Chief Human Resources Officer | $595,582.00 | — | 59 | $18,663.00 | 0.06% |
Jeff Ehrhard | Senior Vice President & GM of North America | — | — | — | — | — |
Roberto de Mezerville | Chief Technology Officer | — | — | 46 | $108,050.00 | 0.37% |
Cassandra E. Harris | Senior VP & CFO | — | — | 53 | $0.00 | <0.01% |
Ivan Bilic | Senior Vice President of Commercial Operations - OUS | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$277,609.65
Sells
34
$37.37M
Net Sentiment
$37.09M
Net selling
Most Active
Chacon Quiros Juan Jose
21 transactions
1–10 of 37
Analysis
Insiders reported 3 buys worth $277,609.65 and 34 sells worth $37.37M over the last 12 months. That adds up to net selling of $37.09M. Chacon Quiros Juan Jose was the most active insider with 21 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | +34.7% | +22.0% (10yr)4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Recent growth has been strongest in Revenue at +34.7% over three years. Forward estimates point to Revenue at +22.0% (10yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Spyre Therapeutics, Inc.
NASDAQ:SYRE
$4.88B
NovoCure Limited
NASDAQ:NVCR
$2.06B
UFP Technologies, Inc.
NASDAQ:UFPT
$1.82B
Zymeworks Inc.
NASDAQ:ZYME
$1.68B
AdaptHealth Corp.
NASDAQ:AHCO
$1.38B
Teladoc Health, Inc.
NYSE:TDOC
$1.32B
Kestra Medical Technologies, Ltd.
NASDAQ:KMTS
$1.22B
CONMED Corporation
NYSE:CNMD
$1.05B
Azenta, Inc.
NASDAQ:AZTA
$1.04B
SS Innovations International, Inc.
NASDAQ:SSII
$672.44M
Who manages ESTA?
Establishment Labs Holdings Inc. (ESTA) lists 8 active executives. The top listed executive is Juan Jose Chacon Quiros, Founder & Executive Director.
Are ESTA insiders buying or selling?
Recent insider activity shows net selling of $27.07M.
Explore More
Continue the stock analysis
Jump to another research area for this company.